Pharmafile - Manufacturing and Production News
Biologic ingredients outstripping chemical counterparts two to three fold
Investment at Roche, Genzyme and Aeras, P&G's warning letter and Takeda's restructuring
Company is also setting aside funds for biotech collaborations
Pfizer's increases its use of contract manufacturing, plus facility news from Wyeth, Abbott, Acceleron, Fresenius Kabi and Althea Technologies
Directorate suspends certificates of suitability of four ingredients
Bid by private equity firm JLL blocked by Ontario Securities Commission
New manufacturing process approved but concerns raised over drug's future